ABSTRACT: Antibiotic resistance poses a critical threat to global health care. Alkyl-and aryltriazene compounds have found utility as DNA-modifying agents and have been previously 2 assessed as potential anti-cancer therapeutics. However, their potential utility as antimicrobials has only recently been appreciated. Therefore, to further investigate the efficacy of these compounds as antibiotics, we synthesized a series of forty six diaryltriazene derivatives and evaluated their antimicrobial properties. Initial experiments showed activity of some diaryltriazene compounds against both methicillin-resistant strains of Staphylococus aureus (MRSA) and against Mycobacterium smegmatis with MICs of less than 0.02 and 1 μg/mL. Those diaryltriazene compounds with potent anti-staphylococcal and anti-mycobacterial activity were inactive as growth inhibitors of mammalian cell lines and yeast. Furthermore, we demonstrated that one of the most active anti-MRSA diaryltriazene derivatives was subject to very low frequencies of resistance at < 10 -9 . Whole genome sequencing of resistant isolates identified mutations in the enzyme that lysylates phospholipids. This could result in the modification of phospholipid metabolism and consequently the characteristics of the staphylococcal cell membrane, ultimately modifying the sensitivity of these pathogens to triazene challenge. Our work has therefore extended the potential range of triazenes, which could yield novel antimicrobials with low levels of resistance.
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INTRODUCTION
Historically the discovery of sulphonamides and β-lactam antibiotics triggered the next 50 years of research, during which the majority of antimicrobial agents in use today were discovered. 1 However, the emergence of multidrug-resistance among bacteria including has challenged the effectiveness of antibiotics in the advent of modern medicine. As such, antibiotic resistance has become one of the most serious health care problems in the world. 2 This has been exacerbated by a collapse in antibiotic discovery by global pharma R&D, and resulted in a lack of new antibiotics coming to market. 3, 4 Resistance arises either by alterations to the antibiotic target, by the acquisition of antibiotic modifying enzymes, or by reducing the local concentration of antibiotic via changes in cell wall permeability or efflux.
Considering the above, there is an urgent need to develop new effective antibacterial agents that circumvent the emergence of resistance. 5 Based on our recent research 6 we were prompted to further explore the antimicrobial activity of 1,3-diaryltriazenes. Triazenes possess a number of biological properties, including antifungal, 7 anorexic, 8 and anticancer activity. 9, 10 The mechanism of action of alkyltriazenes is generally connected the formation of reactive diazonium species that are able to alkylate DNA.
11,12
Here we describe the preparation and testing of 46 compounds from the 1,3-diaryltriazene family, including 5 compounds containing an isoniazid (INH) moiety, and 31 compounds containing a fluorine atom, with the potential to be more biologically active than their nonfluorinated analogues. 13 As a result, several triazenes were identified as possesing potent antimicrobial activity towards methicillin resistant S. aureus (MRSA) and M. Smegmatis-a model mycobacterial representative of M. tuberculosis.
RESULTS AND DISCUSSION

Chemistry
A series of 46 triazene derivatives 1-19 were prepared according to Scheme 1, and their structures are depicted in Figure 1 . These include 1,3-diaryltriazenes (1) , their N-acyl substituted derivatives 2-15, including the carbamate 4e, and triazenide salts 16-19.
#R4#The selection of substituents at the triazene 1,3-diphenyl rings was mainly focused on strongly electro-withdrawing groups, in most cases possessing both -I and -R effects, whereas the electron-donating groups were not considered. This selection was stimulated by our recent observation on strong in vitro activity of electron-deficient triazenes against M. tuberculosis. 6 To effectively participate in modulating the electron density, ortho-and/or para-substitution pattern relative to the triazene group was selected predominantly. #R6#Some 1,3-diaryltriazenes were modified by N-acylation. Nicotinoyl (14) , and isonicotinoyl (15) derivatives were tentatively considered as potential multi-target hybrid compounds of 1,3-diaryltriazenes with isoniazid (INH) structures, potentially releasing the isonicotinoyl radical and 1,3-diaryltriazenes. INH is a highly specific first-line TB prodrug, which after activation couples isonicotinoyl radical to NADPH and binds irreversibly to enoylAcpM reductase, blocking cell wall synthesis. 14 In addition to nicotinoyl (14) and isonicotinoyl (15) derivatives, some other acyl analogues 2-13 were considered. Since alkyl triazenes are well known as DNA alkylating agents, 11, 12 17 For a key of substituents, see Figure 1 . 1,3-Diaryltriazenes 1a-h were prepared by treating the appropriately substituted anilines with either sodium nitrite in hydrochloric acid, isoamyl nitrite, or sodium hexanitrocobaltate(III). An acylation of the selected 1,3-diaryltriazenes 1 into N-acyl-1,3-diaryltriazenes 2-15 was achieved by using the appropriate acyl chloride in the presence of triethylamine as a base. Acyl chlorides of nine different aliphatic, aromatic, and heteroaromatic carboxylic acids were selected, including acetyl, chloroacetyl, methoxyacetyl, acetoxyacetyl, benzoyl, fluorobenzoyl, (trifluoromethyl)benzoyl, pentafluorobenzoyl, nicotinoyl, and isonicotinoyl chlorides. In addition, four different triazenide salts were prepared from the diaryltriazene 1a. The reaction with methyl or ethyl propiolate in the presence of triethylamine afforded alkoxycarbonylvinyltriethylammonium salts 16a and 17a, whereas the trituration with triethylamine and potassium hydroxide gave triazenide salts 18a and 19a respectively (Scheme 1).
Antimicrobical properties
Initial susceptibilities to compounds 1-19 were determined for M. smegmatis MC2 155, MRSA USA300 (as a representative of Gram-positive pathogen), E. coli DH10β, as a representative Gram-negative bacterium, and Sacharomyces cervisiae (S. cervisiae) wild strain as a representative eukaryote. The results are presented in Table 1 . None of the examined compounds 1-19 however were found to be toxic towards S. cerevisiae. Figure 2A ). A comparison of the MIC values for the compounds 3a, 3b, and 3d, having a fixed CF3 group at R 2 , indicates that the NO2 group at the position 4 of the 1,3-diphenyl rings is a crucial one, and substituting this group to Cl or CF3 deactivates the compound ( Figure 2B ). The above results suggest that the 4-nitro-2-(trifluoromethyl)phenyl pattern may be the key structural element in identifying the "hit" diaryltriazene compound (R 2 = CF3, R 4 = NO2, Figure 2C ), #R5#at least within the derivatives under this investigation that possess electron-deficient 1,3-diaryl substituents.
Figure 2.
A) The general structure of diaryltriazenes with a variable group R 2 ; B) The general structure of diaryltriazenes with a variable group R 4 ; C) The structure of the parent fragment crucial for the antibacterial activity; D) The effect of "N1 substitution pattern" on antibacterial activity of 1,3-bis(4-nitro-2-(trifluoromethyl)phenyl)triazenes.
Also evident from Table 1 Figure 2D ). The appears not to be important in the activity against MRSA USA300, although this was not found for M. smegmatis (comparing 16a and 17a with 18a and 19a).
Interestingly, some of the examined compounds, notably 14j, showed a significant activity against the wild type E. coli strain (Table 1 ). This observation, although not investigated further here, opens the possibility of discovering novel diaryltriazene derivatives, possessing greater potencies against Gram-negative organisms. This could be particularly important observation given the clinical concern currently associated with multi-drug resistant Gram-negative infections.
As non-specific bactericidal activity usually corresponds to the lack of prokaryotic specificity and therefore potential toxicity in mammals, 21 we decided to focus on identifying potentially membrane-damaging diaryltriazenes.
The BacLight™ assay is a particularly useful probe for determining the effect of compounds on bacterial membrane integrity. 22 Ten of the most active diaryltriazenes (1g, 1e, 2a, 3a, 6a, 10a, 16a, 17a, 18a, and 19a) having MICs against MRSA USA300 of less than 2 μg/mL, were selected for testing using this assay. The results of these assays on the cell membrane of this strain are summarized in Table 2 . Here it can be seen that all the tested compounds, with the exception of compound 1, are potentially not membrane damaging. (Table 3 ). This may have been due to a lack of penetration of the tested compounds through the outer membranes of these organisms, or possibly due to efficient efflux functioning. To decipher between these two possibilities we performed MIC evaluations of the selected compounds using an E. coli membrane permeable strain of D22 and an E. coli strain of D22 with knockout of the membrane pump N43 CGSC 5583. The results, presented in Table 4 , suggest that the inactivity of the tested compounds in the case of Gram negative-bacteria, represented by the E. coli DH10β strain, was indeed related to low permeability of the Gram-negative outer membrane to these compounds. #R1# Aberrant behaviour of compounds 6a and 10a could arise from their structure. These compounds are unique amongst those tested from Table 3 , by their possession of (substituted) N-benzoyl group.
Although this may well be an issue that uniquely impinges upon the ability of 6a and 10a to penetrate cells, the explanation of the actions of 6a and 10a may also reside with the E. coli strain D22 used in these experiments. D22 contains a mutation in the LpxC gene which encodes
the synthesis of lipid A. 24, 25 Lipid A is a lipopolysaccharide appended to the outer membrane of E. coli. Perturbations to its synthesis caused by LpxC mutations would likely impact upon the ability of hydrophobic compounds such as 6a and 10a to penetrate the cell. 
#R9#Critically, resistance to methicillin and vancomycin underpins medically intractable infections caused by MRSA and vancomycin resistant enterococci (VRE). The acute diaryltriazene sensitivity of MRSA USA300, a highly resistant clinical MRSA strain, therefore prompted us to investigate the possibility that our antimicrobial diaryltriazene compounds might sensitise these pathogens to -lactams and vancomycin, which would ultimately be of clinical interest. However, no synergism 26 between the compound 16a, one of the most promising new diaryltriazene compounds, was detected when tested with methicillin against MRSA, nor with vancomycin against Vancomycin resistant E. faecalis (VRE). This finding led us to conclude that the mode of action of the diaryltriazene 16a was either unrelated to the action of methicillin and vancomycin (bacterial peptidoglycan biosynthesis) or did not impact on the resistance mechanisms employed by MRSA and VRE towards -lactams and glycopeptides.
In order to better characterise the mode of action of the compound 16a, MRSA strain USA300
was grown continuously in the presence of this active compound, at progressively inhibitory concentrations (2-, 4-, 6-and 8-times it's MIC value), allowing resistance to develop. Following incubation three 16a-resistant MRSA USA300 isolates were obtained. In addition the mutation rate of the MRSA USA300 strain when exposed to the different concentrations of the compound 16a was also determined. #R2#We have also obtained MICs values of all three resistant isolates (Table 5 ). / / a Mutation rate assays were performed using MRSA USA300 strain.
MRSA USA300 isolates resistant to the compound 16a, and sensitive parental strains were subjected to whole genome sequencing in order to identify the underlying genetic polymorphisms present in resistant isolates. Resistant isolates (identified as Isolates R1, R2, and R3) were compared to the parental (control) strain, allowing the genetic polymorphisms differentiating these isolates to be identified ( Figure 3 ). 27 This molecule consists of a hydrophobic Cterminal, thought to be embedded within the cell membrane, flanked at the N-terminal end by a charged tail. 28, 29 The mechanism by which this protein reduces its sensitivity to the diaryltriazene 16a therefore remains unclear; its surface location could however affect the interaction or permeability of the cell to this compound. 
33
The thymine insertion at position 2496195 occurred in an intergenic region prior to the possible transcriptional regulator described above, on the forward strand, and upstream from a hypothetical membrane protein on the reverse strand. Using the prediction software PEPPER 34 this region was predicted to contain a promoter sequences in the forward direction. 33 This suggested that expression levels for the predicted transcriptional regulator could have been affected. However, it remains unclear as to how mutations in a gene associated with tetracycline resistance impact upon diaryltriazene resistance.
Therefore, no single target could be identified for the activity of the compound 16a. Instead, changes in MIC appear to have resulted from independent mechanisms unique to each mutant isolate. To assess the specificity and translational benefit that might arise from antimicrobials based upon the diaryltriazene compounds used in this research we assessed the impact of the most promising triazenide salt 16a, as well as 17a, 18a, and 19a on human keratinocytes. The results ( Figure 4) show that keratinocytes survived significantly higher concentrations of triazenide salts compared to those concentrations which inhibited the growth of MRSA USA300, M. smegmatis (Table 1) , MRSA wild strain, S. pneumoniae, Bacillus subtilis or Vancomycin resistant E. faecalis (Table 3 ). This data clearly indicates a marked selectivity of these diaryltriazenes towards bacterial growth inhibition. It is interesting to note that the structures of 1,3-diaryl substituents at the triazenes identified in this work has a similarity with benzothiazinones (BTZ043) and related compounds. antitubercular activity, it was found that these compounds need to be functionalized with nitro group as well as a meta-electron-withdrawing group, typically either a trifluoromethyl or another nitro. The nitroaromatic group was postulated to undergo bioreduction to a corresponding nitrosoarene which then reacts with an active site cysteine residue in the DprE1 enzyme to form a semimercaptal adduct inactivating the enzyme. 14, 35, 38 Recent chemical studies on BTZ043 confirmed the postulated reactivity, indicating that thiolates and other nucleophiles induce nonenzymatic reduction of the nitro groups to the corresponding nitroso intermediates. 39 We conducted NMR experiment where equimolar amounts of reduced glutathione (GSH) and triazenide salt 19a were incubated at room temperature in a mixture of DMSO-d6 and phosphate buffer of pH 7.4 (1:1, v/v). The reaction mixture was monitored by 1 H NMR spectroscopy for 24
h indicating no changes in the aromatic region of the spectra. This suggests that the molecular mechanism of action of 1,3-diarlytriazenes under this investigation may be different to that of BTZ043.
The biological activity of alkyltriazenes has been associated to degradation products involved, forming reactive diazonium species. 11, 12 In contrast, compounds 1a and 19a were found to be stable in phosphate buffer solutions at pH 7.4 with no detectable decomposition as indicated by TLC and NMR analyses. Thus, the molecular mechanism of antibacterial activity of 1,3-
diaryltriazenes is yet to be explored, and will be the subject of forthcoming investigations.
CONCLUSIONS
Here we have described the synthesis of a library of 1,3-diaryltriazenes, their N-acyl derivatives, and their salts. The structure-activity relationships (SAR) of these compounds revealed that the antimicrobial properties of these compounds depended on the type of substituent group attached to the two constituent benzene rings. Specifically, a trifluoromethyl group at position 2, and a nitro substituent at position 4 of the triazene were found to be critical to its activity.
Regarding the biological activities of the new compounds, the most important result from our study was that the selected compounds 16a, 17a, 18a and 19a were extremely active against one of the most clinically important bacterial species, MRSA. These compounds were not found to be membrane damaging to MRSA USA300. The molecular basis of the triazene activity against S. aureus remained unclear, with the appearing to more than one mechanism of killing based on the observed mutations identified among resistant isolates. Where a mechanism could be characterized, it appeared that changes in the phospholipid composition of the staphylococcal cell membrane were ultimately responsible. In addition, the selected compounds were found to be very effective against other Gram-positive bacteria, such as S. pneumoniae, B. subtilis,
Vancomycin resistant E. faecalis, and M. smegmatis. Promising activities of a number of the triazene family compounds towards E. coli were also found. The majority of the tested compounds were however inactive against Gram-negative organisms, with membrane penetration found to be limiting in E. coli.
These compounds were also found to be inactive against lower eukaryotes (yeast), and more importantly, exhibited only a low cytotoxicity against human keratinocytes (as compared to the cytotoxicity observed towards certain pathogenic bacteria). These characteristics are promising with respect to the potential clinical utility of these triazenes for use as novel antimicrobials. Our data suggest that 1,3-diaryltriazenes could represent a new class of antibacterial drug. 2i, 2j, 3k, 5k, 7k, 8k, 10k, 12k , 14i-l, 15i-l, were synthesized as described in the literature. 
EXPERIMENTAL SECTION
Chemistry
Preparation of 1,3-bis(2,4-bis(trifluoromethyl)phenyl)triazene (1b
General procedures for the synthesis of 3-acyl-1,3-diaryltriazenes 2-15
Method A. (3b, 3d, 3k) Triethylamine (0.279 mL, 2 mmol) was added to a stirred suspension of the appropriate triazene 1 (1 mmol) in acetonitrile (10 mL) at room temperature, followed by the addition of chloroacetyl chloride (0.155 mL, 2 mmol). After additional stirring for 10 min, the reaction mixture was evaporated to dryness under reduced pressure. Then, water (5 mL) was added and the water phase was washed with dichloromethane (3 × 10 mL). Combined organic phases were first washed with water (20 mL) and then dried over anhydrous Na2SO4, filtered and evaporated under reduced pressure to dryness yielding the crude products 3. Thereafter, products were recrystallized using the appropriate solvents.
Method B. (14, 15) Triethylamine (0.558 mL, 4 mmol) was added to a stirred suspension of the appropriate triazene 1 (1 mmol) in dry acetonitrile (20 mL) at room temperature, followed by the addition of nicotinoyl chloride (isonicotinoyl chloride in cases of 15). After additional stirring for 10-20 min, the reaction mixture was evaporated to dryness under reduced pressure, treated with methanol, filtered off and washed with saturated NaHCO3 solution and methanol yielding the crude products 14 and 15. Thereafter, all products were recrystallized using the appropriate solvents.
General procedures for the synthesis of triazenide salts 16-19
Method C. (16, 17) Triethylamine (0.558 mL, 4 mmol) was added to a stirred suspension of 1,3-bis(4-nitro-2-(trifluoromethyl)phenyl)triazene (1a) (0.424 g, 0.5 mmol) in acetonitrile (7 mL) at room temperature followed by the addition of methyl propiolate (ethyl propiolate in the case of 17a). After additional stirring for 1 h, the reaction mixture was evaporated to dryness under reduced pressure, treated with diethyl ether and filtered off, yielding the crude products 16a and 17a. Thereafter, both products were recrystallized using the appropriate solvents.
Method D. (19)
A solution of KOH (0.224 g, 4 mmol) in water (20 mL) was added to a stirred solution of 1,3-bis(4-nitro-2-(trifluoromethyl)phenyl)triazene in acetonitrile (10 mL) at room temperature. After additional stirring for 20 min, acetonitrile was evaporated under reduced pressure, and the precipitate was filtered off, yielding 19a. A crude product was recrystallized from acetonitrile/water mixture. μg/mL) were tested in all possible combinations.
1-(1,3-Bis(2,4-bis(trifluoromethyl)phenyl)triaz-2-en-1-yl)-2-chloroethanone (3b
1-(1,3-Bis(2-bromo-4-nitrophenyl)triaz-2-en-1-yl)-2-chloroetanone (3k
3-Ethoxy-N,N,N-triethyl-3-oxoprop-1-en-1-aminium 1,3-bis(4-nitro-2-(trifluoromethyl) phenyl)triaz-2-en-1-ide (17a
Mutation frequency determination. Assays were carried out in triplicate. MRSA USA300
inoculums were prepared in 15 mL LB broth as described above (see "Bacterial Strains and
Growth Conditions" section). After a 18-20 h incubation at 37 °C, cultures were subjected to serial tenfold dilutions in sterile PBS buffer. For cell counting, 100 μL of each dilution was plated on BHI non-selective solid media. Cell numbers were determined following a 20-24 h incubation at 37 °C, by performing colony counts on the agar plates. For mutant cell counting 100 μL of each dilution was plated onto selective BHI solid media containing active compound 16a (0.03125 μg/mL, 0.0625 μg/mL, 0.09375 μg/mL or 0.125 μg/mL). Colony counts were then performed as above. The mutation rate value was calculated as the ratio between the resistant bacterial cell counts to the parental culture cell counts.
Genomic DNA extraction. DNA was obtained from MRSA USA300 resistant strains obtained from the mutation rate assays. First, strains were continuously grown on selective BHI solid media plates for 20-24 h at 37 °C, with the appropriate concentration of the compound 16a, for 10 days. DNA extraction was performed using a Wizard Genomic DNA Purification Kit (Promega) according to the manufacturer's instructions. As lytic enzymes, both lysozyme (60 μL, 10 μg/mL) (Sigma Aldrich) and lysostaphin (60 μL, 1 μg/mL) (Sigma Aldrich) were used.
Whole genome sequencing. 16a-Resistant MRSA USA300 strains were used. Short reads were generated using the Illumina MiSeq platform. The genome sequence of the closely related S. aureus USA300_TCH1516, available from the NCBI archive, 43 was used as a reference. Short reads were aligned to the reference genome using SMALT. 44 SNP's were identified based on the criteria described by Harris and colleagues. 45 Briefly, only bases with a Phred quality score above 50 were assessed (corresponding to a 99.999% base calling accuracy; www.phrap.org;
www.illumina.com). A SNP was called if more than 75% of four or more reads (at least two reads aligning to the forward and reverse strand) supported the SNP. The site was otherwise identified as missing data. Short sequence insertions and deletions (indels) were identified both during the SMALT alignment process, and from using the program PINDEL 46 to identify split reads i.e. where only part of a read mapped to the reference.
On average, over 99.09% of reads mapped to the chosen reference. Variation was then filtered so that mutant isolates could be compared directly to the control isolate (MRSA USA300) used in the laboratory assays.
In vitro cytotoxicity assay. The compound cytotoxicity was determined on the culture of primary normal human keratinocytes. Cells were grown as a monolayer culture in Dulbecco's modified Eagle's medium, DMEM (GIBCO), supplemented with 10% (v/v) fetal serum (GIBCO) at 37 °C with 5% (v/v) CO2. Cellular sensitivity to the most promising compounds was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. 47 Cells were seeded in 96-well tissue culture plates (3000 cells/0.18 mL medium/well) and incubated for 24 h. The compounds were dissolved in DMSO and diluted with growth medium to different concentrations, 20 μL of each dilution being added to each well. The highest DMSO % that we applied was 0.25%, which was not toxic to cells in the MTT assay. Each concentration was tested in quadruplicate. Following a 72 h incubation at 37 °C, the medium was aspirated, and 20 μg of MTT dye/0.04 mL medium was added to each well. Four hours later, formazan crystals were dissolved in DMSO (0.17 mL/well), and the plates were mechanically agitated for 5 min. The optical density at 545 nm was determined on a microtiter plate reader (Awareness Technology Inc.), with each experiment being repeated three times. 
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